CIA
INSY

Capital Impact Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Capital Impact Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-12,984
Closed -$274K – 323
2014
Q4 		$274K Hold
12,984
– – 0.13% 95
2014
Q3 		$252 Hold
12,984
– – ﹤0.01% 89
2014
Q2 		$203K Buy
+12,984
New +$210K 0.15% 92

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital Impact Advisors's INSY Position: Q1 2015 in Review

Capital Impact Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q1 2015, closing a stake of 12,984 shares — an estimated $274K sold.

Capital Impact Advisors first reported a position in INSY in Q2 2014 and held it in 3 quarters. The position peaked at $274K in Q4 2014. 133 funds tracked by Wall St. Rank hold INSY as of Q1 2015.

  • Capital Impact Advisors reported no remaining Insys Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 12,984 Insys Therapeutics, Inc. shares in Q1 2015, an estimated $274K.
  • Capital Impact Advisors first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's Insys Therapeutics, Inc. position peaked at $274K in Q4 2014.
  • 133 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.